Article
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
Neuro-oncology - 1 Apr 2006
Shimato Shinji, Mitsudomi Tetsuya, Kosaka Takayuki, Yatabe Yasushi, Wakabayashi Toshihiko, Mizuno Masaaki, Nakahara Norimoto, Hatano Hisashi, Natsume Atsushi, Ishii Dai, Yoshida Jun
Abstract excerpt
Gefitinib--a specific inhibitor of epidermal growth factor receptor (EGFR)-associated tyrosine kinase--has demonstrated efficacy in a subgroup of patients with non-small-cell lung carcinoma (NSCLC) who fail conventional chemotherapy. It is also reported to have an antitumor effect in brain metastases from NSCLC. Additionally, EGFR mutations have shown a strong association with gefitinib sensitivity for NSCLC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
